First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 894 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... July 25, 2024 A celebration of peer review September 21, 2021 Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... October 9, 2024 Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer January 30, 2023 Load more HOT NEWS New Task Force Focuses on Quality of Life for AYAs with... Precision drug slows progression of advanced breast cancer ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... Football Player Scores 8 Touchdowns the Day After His Mom Dies...
